OSE Immunotherapeutics Share Price
Stocks
OSE
FR0012127173
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Euronext Paris
16:55:00 29/09/2026 BST
|
Pre-market 07:28:41 | |||
| 2.252 EUR | -4.90% |
|
2.258 | +0.27% |
| Market Cap | 52.97M 60.02M 50.11M 45.45M 85.21M 5.76B 86.05M 601M 232M 2.94B 225M 220M 9.46B | P/E 2026 * |
-1.73x | P/E 2027 * | -1.98x |
|---|---|---|---|---|---|
| Enterprise Value | 93.76M 106M 88.71M 80.45M 151M 10.19B 152M 1.06B 410M 5.21B 399M 390M 16.75B | EV / Sales 2026 * |
19.1x | EV / Sales 2027 * | 11x |
| Free-Float |
78.15% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| OSE | Real-time | |
CBOE
| OSEp | Real-time | |
|
Tradegate
| 6OP | Real-time | |
|
Deutsche Boerse AG
| 6OP | Delayed | |
|
Börse Stuttgart
| 6OP | Delayed | |
|
CBOE
| 0RAD | Real-time | |
|
Boerse Muenchen
| 6OP | Real-time |
Last Transcript: OSE Immunotherapeutics
| 1 day | -4.90% | ||
| 1 week | -12.78% | ||
| Current month | -29.98% | ||
| 1 month | -29.40% | ||
| 3 months | -27.35% | ||
| 6 months | -25.87% | ||
| Current year | -56.27% |
| 1 week | 2.19 |  | 2.64 |
| 1 month | 2.19 | | 3.32 |
| Current year | 2.19 | | 5.9 |
| 1 year | 2.19 | | 7.7 |
| 3 years | 2.19 | | 11.58 |
| 5 years | 2.19 | | 12.28 |
| 10 years | 2.19 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Bozec
CEO | Chief Executive Officer | - | 01/10/2025 |
Thomas Gidoin
DFI | Director of Finance/CFO | 43 | 19/08/2025 |
Silvia Comis
CTO | Chief Tech/Sci/R&D Officer | - | 19/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Maryvonne Hiance
BRD | Director/Board Member | 77 | 30/05/2016 |
Brigitte Dreno
BRD | Director/Board Member | 73 | 13/06/2017 |
| Director/Board Member | - | 21/06/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 13/11/24 | Sell | Director | 30,000 | 0.1375% | ||
| 12/11/24 | Sell | Chief Administrative Officer | 10,000 | 0.0458% | ||
| 21/06/24 | Exercice | Director | 10,000 | 0.0459% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.90% | -12.78% | -62.15% | -47.14% | 60.02M | |
| -0.03% | +3.77% | +12.35% | +37.22% | 48.85B | |
| -0.73% | -0.41% | +48.84% | +36.72% | 44.28B | |
| +1.36% | +6.03% | +343.85% | +638.73% | 43.83B | |
| -0.47% | -0.76% | +9.75% | +103.07% | 41.53B | |
| +0.34% | +0.22% | +5.18% | +47.36% | 30.13B | |
| +1.00% | -1.28% | +24.23% | +156.93% | 17.36B | |
| -3.20% | -3.50% | +25.33% | +42.43% | 14.99B | |
| -2.94% | +6.98% | +5.10% | - | 14.9B | |
| -0.86% | -4.00% | - | - | 14.98B | |
| Average | -1.04% | -0.73% | +45.83% | +126.92% | 27.09B | |
| Weighted average by Cap. | -0.26% | +1.20% | +75.29% | +168.04% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.9M 5.55M 4.64M 4.2M 7.88M 533M 7.96M 55.62M 21.44M 272M 20.85M 20.4M 876M | 10.53M 11.93M 9.96M 9.04M 16.94M 1.14B 17.11M 120M 46.06M 585M 44.8M 43.83M 1.88B |
| Net income | -30.59M -34.66M -28.94M -26.24M -49.2M -3.33B -49.69M -347M -134M -1.7B -130M -127M -5.47B | -21.47M -24.33M -20.31M -18.42M -34.53M -2.33B -34.88M -244M -93.91M -1.19B -91.34M -89.35M -3.84B |
| Net Debt | 40.79M 46.22M 38.59M 35M 65.62M 4.44B 66.27M 463M 178M 2.26B 174M 170M 7.29B | 63.08M 71.48M 59.69M 54.13M 101M 6.86B 102M 716M 276M 3.5B 268M 263M 11.27B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/09/26 | €2.252 | -4.90% | 144,968 |
| 28/09/26 | €2.368 | +5.62% | 413,805 |
| 25/09/26 | €2.242 | -8.86% | 320,479 |
| 24/09/26 | €2.460 | -5.31% | 104,668 |
| 23/09/26 | €2.598 | +0.62% | 360,766 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- OSE Stock
Select your edition
All financial news and data tailored to specific country editions
